Mervyn Edward Griffin Jr., a true pioneer in the television industry, passed away Sunday morning lengthy battle with prostate cancer. He was 82.

Friends say he impacted almost every corner of TV programming for decades. If he wasn’t in front of a crowd, he was behind the camera or behind the scenes, credited with shaping the television world.

Griffin began his TV career over half a century ago. His number one hit “I’ve Got a Lovely Bunch of Coconuts” propelled his career in 1950.

He launched Jeopardy! in the 1960’s, and the show still brings good ratings even today. The broadcasting pioneer sold his shows in 1986, as well as Merv Griffin Enterprises. They went for a reported value of $250 million, and a share of future profits. It was reported that Griffin made $80 million in royalties alone for composing the theme song to Jeopardy!.

Merv Griffin was initially diagnosed with prostate cancer in 1996. He made good progress against the cancer but then his condition declined rapidly, and by Friday he was reported to be in grave condition.

Merv Griffin is survived by his only son, Anthony. “My father was a visionary,” he said. “He loved business and continued his many projects and holdings even while hospitalized.”

FRIDAY, March 2 (HealthDay News) — A component of green tea, combined with low doses of the cox-2 inhibitor painkiller Celebrex, may be able to slow prostate cancer growth, according to a U.S. study.

Previous research found that, individually, both the green tea polyphenol epigallocatechin-3-gallate (EGCG), a known antioxidant, and cox-2 inhibitors helped fight prostate cancer in animals.

In this study of cultured human prostate cancer cells and mice, researchers at the University of Wisconsin-Madison found that a combination of EGCG and the cox-2 inhibitor celecoxib (Celebrex) was 15 percent to 28 percent more effective in slowing the growth of cancer cells than either agent alone.

The study, which was funded by the U.S. National Cancer Institute, was published March 1 in the journal Clinical Cancer Research.

“Celecoxib and green tea have a synergistic effect — each triggering cellular pathways that, combined, are more powerful than either agent alone. We hope that a clinical trial could lead to a preventative treatment as simple as tea time,” Hasan Mukhtar, professor of dermatology and a member of the Paul Carbone Comprehensive Cancer Center, said in a prepared statement.

“Prostate cancer typically arises from more than one defect in the cellular mechanics, which means that a single therapeutic might not work fighting a particular cancer long-term. If tests in human trials replicate (the results of this study), we could see a powerful combined therapy that is both simple to administer and relatively cost effective,” Mukhtar said.